Evogene (E3V) Q2 2026 Earnings Report

The call communicated substantial operational and technological progress: a focused shift to ChemPass, meaningful cost and headcount reductions, important platform upgrades (AI agents, predictive models), expanded virtual chemical space, and multiple collaboration agreements validating the platform. These positives are tempered by significant near-term financial and commercialization challenges — materially lower revenue versus prior year, a limited cash balance relative to expected burn, noncash warrant-related accounting volatility, program discontinuation (APTH1), and shareholder governance pressure. Management highlighted actions to raise capital, monetize noncore assets, expand investor outreach, and pursue partnerships, but timelines to convert technological progress into material revenue remain uncertain.

Management reiterated financial and operational guidance: full‑year 2026 consolidated cash usage is expected to be approximately $8.5–$9.5 million (Q2 cash usage ~$2.1M; cash & cash equivalents as of June 30, 2026 ~$9.3M) with further burn reductions anticipated in 2027 after lowering burn from ~ $20.5M in 2024 to the 2026 guidance; headcount has been cut from 117 to 38 and ~ $11.1M in new capital was raised (ATM proceeds ~ $0.8M in Q2 and ~$2.4M in Q3 2026); H1 2026 revenue was ~$0.7M (Q2 ~$0.3M) vs. $2.9M in H1 2025, net loss Q2 2026 was ~$1.8M (vs. $4.7M Q2 2025) and net loss H1 2026 was ~ $7.7M, R&D (net of grants) H1 ~$2.9M (Q2 ~$1.4M), S&M H1 ~$0.7M (Q2 ~$0.3M), G&A H1 ~$2.0M (Q2 ~$0.9M), financing results affected by warrant accounting (H1 recorded ~ $3.8M of finance expense and ~$2.1M of financing income), loss from discontinued operations H1 ~$0.5M (Q2 ~$0.2M); operational targets include monetization and advancement of ChemPass (virtual chemical space expanded from 36B to 110B molecules, 6 active collaborations—4 signed this year—with Hit ID completed in 2, internal programs advanced from Hit‑to‑Lead to Lead Optimization/step 3 and an anticipated move into preclinical for at least one program in H2 2027, and an Ag Septoria fungicide program nearing completion of step 3 ahead of greenhouse and field trials).